What is the initial dose of Cardizem (diltiazem) IV bolus for atrial fibrillation (AFib) with rapid ventricular response (RVR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Dosing of IV Diltiazem for Atrial Fibrillation with Rapid Ventricular Response

The initial dose of IV diltiazem for atrial fibrillation with rapid ventricular response is 0.25 mg/kg actual body weight administered over 2 minutes (approximately 15-20 mg for an average patient). 1

Dosing Protocol

Initial Bolus

  • 0.25 mg/kg actual body weight administered over 2 minutes 1, 2
  • For a typical adult, this translates to approximately 15-20 mg

Follow-up Dosing

If the initial dose is inadequate after 15 minutes:

  • Second bolus: 0.35 mg/kg actual body weight over 2 minutes (approximately 25 mg) 1, 2
  • Some patients may respond to a lower initial dose of 0.15 mg/kg, though duration of action may be shorter 1

Continuous Infusion

If continued rate control is needed:

  • Start at 5-15 mg/hour IV infusion 2, 1
  • Typical starting rate: 10 mg/hour 1
  • May titrate in 5 mg/hour increments up to 15 mg/hour as needed 1
  • Infusion may be maintained for up to 24 hours 1

Efficacy and Safety Considerations

Efficacy

  • Response rates to initial bolus dosing are high, with approximately 94% of patients achieving >20% reduction in heart rate, conversion to sinus rhythm, or heart rate <100 beats/min 3
  • Target heart rate is generally considered controlled when ventricular response is between 60-80 bpm at rest and 90-115 bpm during moderate exercise 2

Safety Considerations

  • Monitor for hypotension, which is a common side effect 2
  • Lower doses (≤0.2 mg/kg) may provide similar efficacy with reduced risk of hypotension compared to standard doses 4
  • Avoid in patients with heart failure with reduced ejection fraction (HFrEF) 2, 5
  • Use caution in patients with impaired ventricular function 2

Special Populations and Considerations

Elderly or Low Body Weight

  • Patients with low body weights should be dosed strictly on a mg/kg basis 1
  • Consider starting at the lower end of the dosing range

Transition to Oral Therapy

  • For continued rate control, oral diltiazem can be started while IV infusion is maintained
  • Oral maintenance dose: 120-360 mg daily in divided doses 2
  • IV infusion can be discontinued 4 hours after the first oral dose 6

Important Cautions

  • Do not use in patients with pre-excited atrial fibrillation (with accessory pathway) as it may accelerate ventricular response 2
  • Avoid in patients with severe hypotension, cardiogenic shock, or acute heart failure 2
  • Monitor blood pressure and heart rate continuously during administration
  • Have resuscitation equipment readily available due to risk of significant hypotension

By following this evidence-based dosing protocol, you can effectively manage patients with atrial fibrillation and rapid ventricular response while minimizing adverse effects.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Low-dose diltiazem in atrial fibrillation with rapid ventricular response.

The American journal of emergency medicine, 2011

Guideline

Atrial Fibrillation Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.